Supraventricular tachycardia AHA recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways: Difference between revisions
Jump to navigation
Jump to search
Aysha Aslam (talk | contribs) (Created page with "__NOTOC__ {{Supraventricular tachycardia}} {{CMG}} {{AE}}{{AA}} ==Overview== ==Management of Symptomatic Patients With Manifest Accessory Pathways== ==References== {{Reflist|2}}") |
Aysha Aslam (talk | contribs) |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Management of Symptomatic Patients With Manifest Accessory Pathways== | ==Management of Symptomatic Patients With Manifest Accessory Pathways== | ||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''In symptomatic patients with pre-excitation, the findings of abrupt loss of conduction over the pathway during exercise testing in sinus rhythm ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-R ]])'' <nowiki>"</nowiki> or intermittent loss of pre-excitation during ECG or ambulatory monitoring ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD ]])'' <nowiki>"</nowiki> are useful for identifying patients at low risk of developing rapid conduction over the pathway.<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: ]])'' <nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''An EP study is useful in symptomatic patients with preexcitation to risk-stratify for life threatening arrhythmic events<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-NR ]])'' <nowiki>"</nowiki> | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 17:10, 26 October 2016
Supraventricular tachycardia Microchapters |
Differentiating Among the Different Types of Supraventricular Tachycardia |
---|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
Diagnosis |
Treatment |
2015 ACC/AHA Guideline Recommendations |
Case Studies |
Supraventricular tachycardia AHA recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways On the Web |
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Symptomatic Patients With Manifest Accessory Pathways |
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of Symptomatic Patients With Manifest Accessory Pathways
Class I |
"1.In symptomatic patients with pre-excitation, the findings of abrupt loss of conduction over the pathway during exercise testing in sinus rhythm (Level of Evidence:B-R ) " or intermittent loss of pre-excitation during ECG or ambulatory monitoring (Level of Evidence:C-LD ) " are useful for identifying patients at low risk of developing rapid conduction over the pathway."(Level of Evidence: ) " |
"2.An EP study is useful in symptomatic patients with preexcitation to risk-stratify for life threatening arrhythmic events"(Level of Evidence:B-NR ) " |